|
Market Closed -
Nasdaq
21:00:00 01/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 9.920 USD | +2.27% |
|
+0.92% | +27.18% |
| 08-25 | BioCryst Pharmaceuticals Announces Approval Of ORLADEYO For Pediatric HAE Patients In Japan | CI |
| 08-25 | BioCryst Pharmaceuticals Gets Japan Approval for Orladeyo in Young Children | MT |
Company Valuation: BioCryst Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,492 | 2,140 | 1,227 | 1,558 | 1,642 | 2,535 | - | - |
| Change | - | -14.12% | -42.68% | 26.97% | 5.43% | 54.36% | - | - |
| Enterprise Value (EV) | 2,124 | 2,140 | 1,654 | 2,065 | 1,642 | 2,535 | 2,535 | 2,535 |
| Change | - | 0.77% | -22.74% | 24.91% | -20.49% | 54.36% | 0% | 0% |
| P/E | -13.4x | -8.63x | -5.08x | -17.5x | 6.45x | -4.32x | 14.9x | 11.8x |
| PBR | -23.9x | -7.32x | -2.71x | -3.27x | - | -8.12x | -218x | 5.38x |
| PEG | - | -0.3x | 0.5x | 0.3x | -0x | 0x | -0x | 0.4x |
| Capitalization / Revenue | 15.9x | 7.9x | 3.7x | 3.46x | 1.88x | 3.61x | 3.44x | 3.03x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 3.61x | 3.44x | 3.03x |
| EV / EBITDA | -0x | -0x | -0x | -0x | 0x | -5.09x | 12.4x | - |
| EV / EBIT | -0x | -0x | -0x | -0x | 0x | -4.99x | 10.3x | 7.86x |
| EV / FCF | -0x | -0x | -0x | -0x | 0x | -41x | 9.2x | 6.38x |
| FCF Yield | -5.8% | -7.63% | -7.93% | -3.41% | 21% | -2.44% | 10.9% | 15.7% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.03 | -1.33 | -1.18 | -0.43 | 1.21 | -2.296 | 0.6647 | 0.8435 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 157.2 | 270.8 | 331.4 | 450.7 | 874.8 | 702.2 | 737.3 | 837.3 |
| EBITDA 1 | -176.9 | -147 | -102.1 | -1.297 | 342.4 | -497.8 | 204.5 | - |
| EBIT 1 | -177.7 | -148.4 | -103.7 | -2.543 | 341 | -508.2 | 247.2 | 322.4 |
| Net income 1 | -184.1 | -247.1 | -226.5 | -88.88 | 263.9 | -578.8 | 184.4 | 253.9 |
| Net Debt | -368.3 | - | 426.7 | 507.7 | - | - | - | - |
| Reference price 2 | 13.850 | 11.480 | 5.990 | 7.520 | 7.800 | 9.920 | 9.920 | 9.920 |
| Nbr of stocks (in thousands) | 179,936 | 186,424 | 204,809 | 207,133 | 210,543 | 255,535 | - | - |
| Announcement Date | 23/02/22 | 21/02/23 | 26/02/24 | 24/02/25 | 26/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.32x | - | - | -.--% | 2.53B | |
| 20.2x | 7.1x | 14.34x | 1.44% | 68.21B | |
| 36.48x | 9.51x | 29x | 0.04% | 64.25B | |
| -74.38x | 14.34x | -69.16x | -.--% | 26.54B | |
| -15.61x | 5.93x | -7.46x | -.--% | 25.61B | |
| 27.16x | 5.09x | 16.92x | -.--% | 19.88B | |
| 49.41x | 18.23x | 36.98x | 0.31% | 17.13B | |
| 1290.27x | 37.31x | 814.28x | -.--% | 14.93B | |
| 17.57x | 5.23x | 12.21x | -.--% | 14.1B | |
| -85.32x | 7.81x | -64.69x | -.--% | 12.45B | |
| Average | 126.15x | 12.28x | 86.94x | 0.18% | 26.56B | |
| Weighted average by Cap. | 79.72x | 10.52x | 50.59x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BCRX Stock
- Valuation BioCryst Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
